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CE Mark approval in September 2011 and to date over 100 commercial implants have been
performed. The device is composed of a porcine biologic valve attached to a self-expanding
nitinol stent designed for simple 2-step implantation and characterized by controlled position-
ing, self-seating in the native annulus resulting in a negligible paravalvular leak rate. The
device was tested in patients at high-risk for mortality with open surgical repair.
Methods: Ninety (90) patients (female69%) with severe aortic stenosis, a mean age of
83.4  4.1 years, all presenting with NYHA Functional Class III or IV and a mean STS
Score of 7.9  4.6 were enrolled in two studies in Germany at 6 centers. Patients are
clinically followed at 7 and 30 days, at 6 and 12 months, and annually thereafter out to
5 years post-implant. The device was successfully implanted in 94.4% of patients (n85)
with a pacemaker implantation rate of 11.1% (n10).
Results: At 12 months the survival rate is 81.1% (n73), the stroke rate is 4.4% (n4),
with no further re-intervention required on the implanted device since procedure. Of the
returning patients, 87% presented with NYHA Functional Class I/II. The mean gradient
at 6 months is 10.3 5.2 mmHg, the mean EOA is 1.5 0.4 cm2 and 77.3% of returning
patients suffered no paravalvular leak, 21.2% exhibit mild paravalvular leak (	1) and only
1 patient possesses a moderate paravalvular leak (	2).
Conclusions: These data confirm the safety profile at one year of this 2nd Generation
TAVI system. We will report the full 12 months results of this multi-center, non-
randomized study of this transapically-placed transcatheter aortic valve at TCT 2012.
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Background: Transcatheter aortic valve implantation (TAVI) has emerged as an
accepted treatment alternative for high risk patients with severe aortic stenosis. This study
was designed to evaluate the safety and efficacy of transapical aortic valve implantation
in high risk patients using the second generation JenaValve TAVI system. It consists of
a biological porcine valve mounted on a self-expanding Nitinol stent. Retrieval capability,
feeler guided anatomically positioning and clipping fixation on the diseased leaflets
provide potential advantages compared to current TAVI systems.
Methods: This study enrolled a total of 73 patients of whom 67 patients (mean age 83.13.9;
Euroscore 28.46.5) underwent elective TAVI at 7 German centers. Primary endpoint was all
cause mortality at 30 days. Procedural success, major adverse cerebrovascular and cardiac
events, functional improvement and echocardiographic valve performance were assessed at
baseline, post-procedure, discharge, 30 day, 3, 6, and 12 months.
Results: 60 of 67 patients underwent successful TAVI with the JenaValve resulting in a
procedural success of 89.6%. Pacemaker implantation for new onset conduction disorders
was necessary in 6 patients (9.1%). No coronary ostium obstructions were seen. TAVI
resulted in favorable reduction of mean transvalvular gradients (40.016.1mmHg vs.
10.07.3mmHg, p 0.0001) and increase in valve opening area (0.70.2cm2 vs.
1.70.6cm2, p 0.0001). None of the successful implanted patients had severe post
procedural aortic regurgitation ( grade 2). Survival at 30 days and 6 months was 92.4%
and 74.3% respectively. Stroke occurred in 4 patients (6.0%) at 6 months. NYHA Class
improved significantly at 6 months after valve implantation (5.4% NYHA class I, 56.8%
NYHA class II and 37.8% with class III). 12 months outcomes will be presented
according to VARC criteria at the conference.
Conclusions: TAVI using the JenaValve system has proven to be an effective treatment
option in high risk patients with aortic stenosis with good short and mid-term outcome.
Anatomically correct positioning and clip-fixation of the native leaflet led to good
hemodynamic function and favorably reduced paravalvular leak rates.
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Background: The Edwards SAPIEN valve has been FDA-approved with its Retroflex
delivery system for retrograde transfemoral (TF) treatment of inoperable patients with
severe aortic stenosis, and is the only device clinically available for transcatheter aortic
valve replacement (TAVR) in the United States (US). Because of insufficient iliofemoral
vascular access, many patients are excluded from the TF approach. We explored
transaortic (TAO) TAVR as an alternate access strategy for these patients.
Methods: Twenty-five consecutive patients underwent TAO TAVR between January
and April, 2012 at our site. All had symptomatic severe aortic stenosis, were inoperable,
and had inadequate vascular access for TF delivery. Through a small upper sternotomy
and direct insertion of the sheath into the ascending aorta, we delivered the valve using the
Retroflex catheter. Procedural and 30-day outcomes were retrospectively compared with
the first 25 patients treated by transapical (TA) access in our program.
Results: TAO TAVR was successfully performed in all patients. One perioperative death
occurred, which was unrelated to the TAO approach. No other cardiovascular death was
reported within 30 days. Compared with TA access, TAO TAVR had a similar all-cause
mortality rate at 30 days, and was associated lower incidence of bleeding events, as well
as shorter ICU length of stay.
BASELINE DEMOGRAPHICS
Trans-Aortic
Series
Trans-Apical
Series P-Value
Median Age (Years 	/SD) 83 (	/5) 85 (	/6) 0.35
Male Gender 10 (40%) 15 (60%) 0.26
Median STS Score (	/SD) 8 (	/4.4) 10.8 (	/3.27) 0.009
Operable for conventional
AVR
0% 100% 0.00
NYHA Class 3 & 4 24 (96%) 25 (100%) 1.00
Median AVA (cm2) 0.62 (	/0.15) 0.60 (	/0.12) 0.62
Median LVEF (%) 60 (	/16) 50 (	/15) 0.38
PROCEDURAL OUTCOMES*
Implantation Success 25 (100%) 25 (100%) 1.00
Moderate or Severe AI or PVL 1 (4%) 4 (16%) 0.35
Emergency open surgery 1 (4%) 1 (4%) 1.00
Procedural Mortality 1 (4%) 0 (0%) 1.00
30-DAY OUTCOMES*
Cardiovascular Mortality 1 (4%) 3 (12%) 0.61
All-Cause Mortality ** 5 (20%) 4 (16%) 1.00
Median ICU Length of Stay 3.0 (	/3.4) 6.0 (	/9.5) 0.013
Median Hospital Length of
Stay
7.0 (	/6.6) 11.0 (	/9.0) 0.069
Myocardial Infarction 0 (0%) 0 (0%) 1.00
Major Stroke 0 (0%) 1 (4%) 1.00
Minor Stroke 1 (4%) 0 (0%) 1.00
Major/Disabling Bleeding 3 (12%) 10 (40%) 0.05
Vascular Access
Complications
2 (8%) 2 (8%) 1.00
Acute Kidney Injury Stage 3 1 (4%) 0 (0%) 1.00
* Adjudicated using VARC criteria.
** 3 pneumonia-related respiratory failure, 1 C. difficile sepsis, 1 procedural death.
Conclusions: TAVR via the TAO approach, using the only commercially-available
device in the US, is technically feasible and is associated with favorable outcomes in
inoperable patients with severe aortic stenosis who are not candidates for TF access. In
these patients, the TAO approach expands the current alternative options for TAVR
access sites. Efforts directed towards enhancing the technologies and techniques associ-
ated with TAO TAVR should further improve the efficacy and safety of this procedure.
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Background: Transcatheter aortic valve replacement is recommended in inoperable
patients with severe, symptomatic aortic stenosis (AS), and is an accepted alternative to
surgical AVR in high risk patients. However, increased stroke, bleeding, vascular
complications and aortic regurgitation (AR) rates may adversely affect outcomes. The
repositionable and fully retrievable Lotus Valve is designed to facilitate accurate
positioning and minimize paravalvular leakage.
Methods: REPRISE I is a prospective, single-arm, 3-center feasibility study to assess
acute safety and performance in symptomatic patients with severe AS at high surgical risk.
The primary endpoint was clinical procedural success (successful implantation without
in-hospital major adverse cardiovascular and cerebrovascular events to discharge or 7
days, whichever came first).
Results: The Lotus Valve was implanted in 11 patients with mean STS and logistic
euroSCOREs of 4.92.5% and 9.54.4%, respectively, and high surgical risk due to
comorbidities/frailty (cognitive dysfunction in 5/11, gait speed 6s in 9/11, grip strength
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18kg in 7/11). At baseline 6 patients were NYHA Class II and 5 were Class III. Clinical
procedural success was achieved in 9/11. One patient experienced a major ischemic stroke
(MRS3 at discharge; final 90-day adjudication pending). A second had a mean
post-procedure gradient of 22mmHg (above the 20mmHg VARC threshold) although the
valve was functioning well (post-procedure AVA 1.6cm2). Partial resheathing
was performed in 4/4 patients; none required full retrieval. Mean aortic gradient
was 53.920.9mmHg at baseline and 13.73.7mmHg at discharge. Mean
AVA was 0.70.2cm2 at baseline and 1.50.2cm2 at discharge. Paravalvular AR
was mild in 2 patients, trivial in 1, absent in 8. Conduction disturbance requiring
a new pacemaker occurred in 4 patients (2 with complete AV block). There were
no deaths or MIs through 7 days.
Conclusions: Early feasibility results suggest that the Lotus Valve can be positioned
precisely and successfully with virtually no AR and low clinical event rates through
discharge, supporting further study in a larger, more rigorous trial. Three-month data will
be presented for the first time at TCT 2012.
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Background: Long-term blood-pressure (BP) monitoring is a vital necessity for
physicians to prescribe appropriate medical treatment for malign hypertension patients in
order to reduce the incidence of secondary consequences such as stroke, kidney failure or
heart insufficiency. However, current devices are still not suited for long-term measure-
ment (several weeks to months). Moreover, they usually measure the peripheral blood
pressure which significantly differs to the central blood pressure known to be the better
indicator for vascular diseases. In order to address this need, we developed and conducted
in-vivo tests on a novel, fully-implantable, wireless blood-pressure monitoring system.
Methods: The monitoring system was tested for six months in 12 chronic ovine models.
The sensor was implanted with X-ray-control in the femoral artery by means of a
dedicated sheath (PASIS). Reference measurements were recorded with gold standard
pressure sensors after implantation. Position and proper functioning of the sensor were
controlled via regular readout measurements and CTs. At the end of each trial, a
histological examination was conducted.
Results: Chronic in-vivo studies revealed that blood pressure measurement over a period
of six months was possible with the novel implantable sensor system. Stable pressure
histories were recorded. However, the mechanical resilience of the sensor system requires
improvement. The in-vivo tests in the femoral artery of sheep produced high stress on the
sensors system. Several implanted systems became inoperative despite efforts to stiffen the
sensor-cable. The histological analysis detected no thrombi. Mild inflammatory reactions
were found at the vessel insertion site in several cases.
Conclusions: The results of the chronic in-vivo tests on the novel fully-implantable
blood-pressure monitoring system were encouraging. Improvements need to be made
regarding the mechanical resilience of the system and the coating. Additional trials at a
modified implantation spot will be conducted in order to reveal further insights regarding
system performance.
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Background: A 10 month research program; to find and validate a relevant unmet
clinical need in cardiovascular care prior to developing solutions.
Methods: A multidisciplinary team of four members with experience in clinical
medicine, engineering, business and software design received four weeks’ training in
basic anatomy, physiology, market analysis, clinical needs finding and concept genera-
tion, intellectual property (I.P.), regulatory, reimbursement and business planning. The
fellows jointly agreed an acceptance criteria e.g. market size, measurable endpoints etc to
aid future decision making. For eight weeks the team were attached to tertiary care
hospitals to understand the patient cycle of care and the perspectives of all the
stakeholders impacting in/out-patient care and to observe a range of in-hospital proce-
dures. This resulted in nearly 2000 observations which were translated into 120 problem
statements. These problems were researched in terms of incidence, prevalence, disease
pathophysiology, existing treatments effectiveness, market size etc. This insight and
filtering against the acceptance criteria enabled further elimination. The remaining
problems were translated into clinical needs statements and validated by speaking to key
stakeholders, in-depth medical literature review and competitor analysis. As a result eight
needs statements emerged. The resultant concepts from brainstorming of the needs were
screened against agreed need specifications and pre-existing I.P. Further literature and
primary research, filtering and elimination led to a final need entitled: A cost effective, fast
way to embolize a blood vessel. This had emerged from observing that current
embolization devices are deficient e.g. need for multiple coils, migration, recanalization,
and high prices.
Results: Funding was successfully applied for and secured from Enterprise Ireland to
enable prototyping with proof of concept via bench testing and animal studies.
Conclusions: This multidisciplinary innovation research program brings together the key
stakeholders involved with medical devices and enables the development of a rich
network and expertise that will promote patient care through future medical device
development.
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Background: A significant proportion of patients with severe mitral regurgitation (MR),
have severe comorbidities and are not candidates for conventional surgery because of high
operative risk. The field of percutaneous mitral valve (MV) repair is developing and many
technologies are now under investigation. To date, trans-catheter valve implantation is
limited to pulmonary and aortic valve replacement. The aim of our study wad to
demonstrate the safety and feasibility of minimally invasive trans-catheter implantation of
a novel self-expanding MV specifically designed for the unique complex anatomical
configuration of the mitral apparatus - the TIARA self-expanding bioprosthetic valve.
Methods: Using a trans-apical approach, TIARA valves were successfully implanted in
29/36 (81%) domestic swine with fluoroscopic and 3D transesophageal echocardio-
graphic (TEE) guidance. Follow-up varied from 90 minutes to 96 hours. The valves were
delivered using a short flexible 30F delivery catheter.
Results: Total procedure time ranged from 17 to 26 minutes, and the prosthesis
deployment time ranged from 5 to 13 minutes. In the 29 successful implantations, TEE
demonstrated excellent function and alignment of the TIARA prosthesis, with no left
ventricular outflow tract obstruction, no pericardial effusion, no encroachment on the
aortic valve, and no trans-valvular gradients. Significant paravalvular leaks were only seen
in cases of either MV annulus-prosthesis mismatch or failed implantation. Macroscopic
evaluation of the explanted hearts demonstrated stable and secure positioning of the valves
in all planes of the mitral apparatus with no evidence of injury to the ventricular or atrial
walls.
Conclusions: We report our successful initial pre-clinical experience with the TIARA
trans-catheter self-expanding mitral bioprosthetic valve. We have demonstrated that the
implantation of the TIARA valve is a feasible, safe, and relatively straightforward
procedure, which results in a stable and well-functioning mitral valve bioprosthesis.
Successful completion of long-term pre-clinical trials of the TIARA is ongoing which will
lead the way to human clinical trials.
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Background: Valvuloplasty (BAV) using the currently available balloons - to prepare
the valve annulus for the implant of a transcatheter heart valve - is associated with balloon
slippage and rupture in up to 17 % of the cases, which carries an increased risk of stroke.
The TRUE Dilatation™ Balloon Valvuloplasty Catheter, constructed of inner and outer
film layers that encompass a flexible matrix center embedded with high performance
fibers, was developed to allow a fast and precise dilatation of the aortic valve in the
absence of balloon rupture. It was aim of the present study to assess the performance of
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